Review





Similar Products

99
ATCC umbilical vascular endothelial cells huvecs
Umbilical Vascular Endothelial Cells Huvecs, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/umbilical vascular endothelial cells huvecs/product/ATCC
Average 99 stars, based on 1 article reviews
umbilical vascular endothelial cells huvecs - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier

95
Cell Applications Inc human vascular umbilical endothelial vein cells huvecs
( A ) Membrane labeling of <t>HUVEC</t> monolayers with CellMask. ( B ) Corresponding fluorescent bead image (beads of size 0.2 μ m ). Arrows indicate bead-related image artifacts ( C ) PIV-UQ displacement field u PIV ( D ) PIV-UQ uncertainty map, σ u , P I V . White regions indicate “bad” PIV windows that were deleted and replaced as described in § 2.2. Uncertainty arrows denote the pointwise angular uncertainty corresponding to 1 circular std. dev. of bootstrapped PIV-UQ distribution. ( E ) Inferred mean marginal posterior traction stress, t ^ ( F ) Marginal posterior traction stress uncertainty field ( σ t ). Uncertainty arrows denote the pointwise angular uncertainty corresponding to 1 circular std. dev. of marginal posterior p ( t | u h ) . Scale bar : 25 μ m
Human Vascular Umbilical Endothelial Vein Cells Huvecs, supplied by Cell Applications Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human vascular umbilical endothelial vein cells huvecs/product/Cell Applications Inc
Average 95 stars, based on 1 article reviews
human vascular umbilical endothelial vein cells huvecs - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier

99
ATCC human umbilical vascular endothelial cells
( A ) Membrane labeling of <t>HUVEC</t> monolayers with CellMask. ( B ) Corresponding fluorescent bead image (beads of size 0.2 μ m ). Arrows indicate bead-related image artifacts ( C ) PIV-UQ displacement field u PIV ( D ) PIV-UQ uncertainty map, σ u , P I V . White regions indicate “bad” PIV windows that were deleted and replaced as described in § 2.2. Uncertainty arrows denote the pointwise angular uncertainty corresponding to 1 circular std. dev. of bootstrapped PIV-UQ distribution. ( E ) Inferred mean marginal posterior traction stress, t ^ ( F ) Marginal posterior traction stress uncertainty field ( σ t ). Uncertainty arrows denote the pointwise angular uncertainty corresponding to 1 circular std. dev. of marginal posterior p ( t | u h ) . Scale bar : 25 μ m
Human Umbilical Vascular Endothelial Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human umbilical vascular endothelial cells/product/ATCC
Average 99 stars, based on 1 article reviews
human umbilical vascular endothelial cells - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier

90
Lonza human umbilical vascular endothelial cells (huvecs, passage 6-7, catalogue no. c2519a)
( A ) Membrane labeling of <t>HUVEC</t> monolayers with CellMask. ( B ) Corresponding fluorescent bead image (beads of size 0.2 μ m ). Arrows indicate bead-related image artifacts ( C ) PIV-UQ displacement field u PIV ( D ) PIV-UQ uncertainty map, σ u , P I V . White regions indicate “bad” PIV windows that were deleted and replaced as described in § 2.2. Uncertainty arrows denote the pointwise angular uncertainty corresponding to 1 circular std. dev. of bootstrapped PIV-UQ distribution. ( E ) Inferred mean marginal posterior traction stress, t ^ ( F ) Marginal posterior traction stress uncertainty field ( σ t ). Uncertainty arrows denote the pointwise angular uncertainty corresponding to 1 circular std. dev. of marginal posterior p ( t | u h ) . Scale bar : 25 μ m
Human Umbilical Vascular Endothelial Cells (Huvecs, Passage 6 7, Catalogue No. C2519a), supplied by Lonza, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human umbilical vascular endothelial cells (huvecs, passage 6-7, catalogue no. c2519a)/product/Lonza
Average 90 stars, based on 1 article reviews
human umbilical vascular endothelial cells (huvecs, passage 6-7, catalogue no. c2519a) - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Cedarlane primary human umbilical vascular endothelial cells (huvecs)
( A ) Membrane labeling of <t>HUVEC</t> monolayers with CellMask. ( B ) Corresponding fluorescent bead image (beads of size 0.2 μ m ). Arrows indicate bead-related image artifacts ( C ) PIV-UQ displacement field u PIV ( D ) PIV-UQ uncertainty map, σ u , P I V . White regions indicate “bad” PIV windows that were deleted and replaced as described in § 2.2. Uncertainty arrows denote the pointwise angular uncertainty corresponding to 1 circular std. dev. of bootstrapped PIV-UQ distribution. ( E ) Inferred mean marginal posterior traction stress, t ^ ( F ) Marginal posterior traction stress uncertainty field ( σ t ). Uncertainty arrows denote the pointwise angular uncertainty corresponding to 1 circular std. dev. of marginal posterior p ( t | u h ) . Scale bar : 25 μ m
Primary Human Umbilical Vascular Endothelial Cells (Huvecs), supplied by Cedarlane, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/primary human umbilical vascular endothelial cells (huvecs)/product/Cedarlane
Average 90 stars, based on 1 article reviews
primary human umbilical vascular endothelial cells (huvecs) - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

99
ATCC vascular endothelial cells huvecs primary umbilical vein endothelial cells
( A ) Membrane labeling of <t>HUVEC</t> monolayers with CellMask. ( B ) Corresponding fluorescent bead image (beads of size 0.2 μ m ). Arrows indicate bead-related image artifacts ( C ) PIV-UQ displacement field u PIV ( D ) PIV-UQ uncertainty map, σ u , P I V . White regions indicate “bad” PIV windows that were deleted and replaced as described in § 2.2. Uncertainty arrows denote the pointwise angular uncertainty corresponding to 1 circular std. dev. of bootstrapped PIV-UQ distribution. ( E ) Inferred mean marginal posterior traction stress, t ^ ( F ) Marginal posterior traction stress uncertainty field ( σ t ). Uncertainty arrows denote the pointwise angular uncertainty corresponding to 1 circular std. dev. of marginal posterior p ( t | u h ) . Scale bar : 25 μ m
Vascular Endothelial Cells Huvecs Primary Umbilical Vein Endothelial Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/vascular endothelial cells huvecs primary umbilical vein endothelial cells/product/ATCC
Average 99 stars, based on 1 article reviews
vascular endothelial cells huvecs primary umbilical vein endothelial cells - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier

99
PromoCell umbilical cord vascular endothelial cell
( A ) Membrane labeling of <t>HUVEC</t> monolayers with CellMask. ( B ) Corresponding fluorescent bead image (beads of size 0.2 μ m ). Arrows indicate bead-related image artifacts ( C ) PIV-UQ displacement field u PIV ( D ) PIV-UQ uncertainty map, σ u , P I V . White regions indicate “bad” PIV windows that were deleted and replaced as described in § 2.2. Uncertainty arrows denote the pointwise angular uncertainty corresponding to 1 circular std. dev. of bootstrapped PIV-UQ distribution. ( E ) Inferred mean marginal posterior traction stress, t ^ ( F ) Marginal posterior traction stress uncertainty field ( σ t ). Uncertainty arrows denote the pointwise angular uncertainty corresponding to 1 circular std. dev. of marginal posterior p ( t | u h ) . Scale bar : 25 μ m
Umbilical Cord Vascular Endothelial Cell, supplied by PromoCell, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/umbilical cord vascular endothelial cell/product/PromoCell
Average 99 stars, based on 1 article reviews
umbilical cord vascular endothelial cell - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier

90
Eppendorf AG human umbilical vascular endothelial cell line (huvec)
( A ) Membrane labeling of <t>HUVEC</t> monolayers with CellMask. ( B ) Corresponding fluorescent bead image (beads of size 0.2 μ m ). Arrows indicate bead-related image artifacts ( C ) PIV-UQ displacement field u PIV ( D ) PIV-UQ uncertainty map, σ u , P I V . White regions indicate “bad” PIV windows that were deleted and replaced as described in § 2.2. Uncertainty arrows denote the pointwise angular uncertainty corresponding to 1 circular std. dev. of bootstrapped PIV-UQ distribution. ( E ) Inferred mean marginal posterior traction stress, t ^ ( F ) Marginal posterior traction stress uncertainty field ( σ t ). Uncertainty arrows denote the pointwise angular uncertainty corresponding to 1 circular std. dev. of marginal posterior p ( t | u h ) . Scale bar : 25 μ m
Human Umbilical Vascular Endothelial Cell Line (Huvec), supplied by Eppendorf AG, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human umbilical vascular endothelial cell line (huvec)/product/Eppendorf AG
Average 90 stars, based on 1 article reviews
human umbilical vascular endothelial cell line (huvec) - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

99
ATCC normal primary human vascular endothelial cells huvec
rhMG53 inhibits vascular <t>endothelial</t> cell migration and tube formation. ( A ) rhMG53 did not induce cellular toxicity in <t>HUVEC</t> up to 100 μg/mL ( n = 5; ** p = 0.01). ( B ) Representative photomicrographs 24 h after scratch wounding, HUVEC treated with 50 μg/mL rhMG53 had significantly less migration and proliferation compared to control ( n = 9). Magnification 4×. ( C ) Quantification of the scratch area remaining at 24 h (**** p < 0.0001). ( D ) Representative photomicrographs and quantification of tube formation when HUVEC was seeded on Matrigel, followed by treatment with VEGF (10 ng/mL) with or without rhMG53 (50 μg/mL) for 18 h. rhMG53 significantly reduced tube length in VEGF-treated HUVEC ( n = 4; ** p = 0.0029). Magnification 4×. ( E ) HUVEC treated with IL-1B (10 ng/mL) with or without rhMG53 have decreased pSTAT3 protein expression; when normalized to total STAT3 expression, rhMG53 significantly (** p = 0.0084) decreased pSTAT3 ( n = 4). Statistical significance was assessed with the Kruskal–Wallis nonparametric test.
Normal Primary Human Vascular Endothelial Cells Huvec, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/normal primary human vascular endothelial cells huvec/product/ATCC
Average 99 stars, based on 1 article reviews
normal primary human vascular endothelial cells huvec - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier

Image Search Results


( A ) Membrane labeling of HUVEC monolayers with CellMask. ( B ) Corresponding fluorescent bead image (beads of size 0.2 μ m ). Arrows indicate bead-related image artifacts ( C ) PIV-UQ displacement field u PIV ( D ) PIV-UQ uncertainty map, σ u , P I V . White regions indicate “bad” PIV windows that were deleted and replaced as described in § 2.2. Uncertainty arrows denote the pointwise angular uncertainty corresponding to 1 circular std. dev. of bootstrapped PIV-UQ distribution. ( E ) Inferred mean marginal posterior traction stress, t ^ ( F ) Marginal posterior traction stress uncertainty field ( σ t ). Uncertainty arrows denote the pointwise angular uncertainty corresponding to 1 circular std. dev. of marginal posterior p ( t | u h ) . Scale bar : 25 μ m

Journal: PLOS Computational Biology

Article Title: Uncertainty-aware traction force microscopy

doi: 10.1371/journal.pcbi.1013079

Figure Lengend Snippet: ( A ) Membrane labeling of HUVEC monolayers with CellMask. ( B ) Corresponding fluorescent bead image (beads of size 0.2 μ m ). Arrows indicate bead-related image artifacts ( C ) PIV-UQ displacement field u PIV ( D ) PIV-UQ uncertainty map, σ u , P I V . White regions indicate “bad” PIV windows that were deleted and replaced as described in § 2.2. Uncertainty arrows denote the pointwise angular uncertainty corresponding to 1 circular std. dev. of bootstrapped PIV-UQ distribution. ( E ) Inferred mean marginal posterior traction stress, t ^ ( F ) Marginal posterior traction stress uncertainty field ( σ t ). Uncertainty arrows denote the pointwise angular uncertainty corresponding to 1 circular std. dev. of marginal posterior p ( t | u h ) . Scale bar : 25 μ m

Article Snippet: Human vascular umbilical endothelial vein cells (HUVECs) (Cell Applications) were cultured in M199 (Gibco) supplemented with 10 % (v/v) endothelial growth medium (Cell Applications), 10 % (v/v) fetal bovine serum (Gibco), and 1 % penicillin-streptomycin (Gibco).

Techniques: Membrane, Labeling

rhMG53 inhibits vascular endothelial cell migration and tube formation. ( A ) rhMG53 did not induce cellular toxicity in HUVEC up to 100 μg/mL ( n = 5; ** p = 0.01). ( B ) Representative photomicrographs 24 h after scratch wounding, HUVEC treated with 50 μg/mL rhMG53 had significantly less migration and proliferation compared to control ( n = 9). Magnification 4×. ( C ) Quantification of the scratch area remaining at 24 h (**** p < 0.0001). ( D ) Representative photomicrographs and quantification of tube formation when HUVEC was seeded on Matrigel, followed by treatment with VEGF (10 ng/mL) with or without rhMG53 (50 μg/mL) for 18 h. rhMG53 significantly reduced tube length in VEGF-treated HUVEC ( n = 4; ** p = 0.0029). Magnification 4×. ( E ) HUVEC treated with IL-1B (10 ng/mL) with or without rhMG53 have decreased pSTAT3 protein expression; when normalized to total STAT3 expression, rhMG53 significantly (** p = 0.0084) decreased pSTAT3 ( n = 4). Statistical significance was assessed with the Kruskal–Wallis nonparametric test.

Journal: Pharmaceutics

Article Title: Development of an Ophthalmic Hydrogel to Deliver MG53 and Promote Corneal Wound Healing

doi: 10.3390/pharmaceutics17040526

Figure Lengend Snippet: rhMG53 inhibits vascular endothelial cell migration and tube formation. ( A ) rhMG53 did not induce cellular toxicity in HUVEC up to 100 μg/mL ( n = 5; ** p = 0.01). ( B ) Representative photomicrographs 24 h after scratch wounding, HUVEC treated with 50 μg/mL rhMG53 had significantly less migration and proliferation compared to control ( n = 9). Magnification 4×. ( C ) Quantification of the scratch area remaining at 24 h (**** p < 0.0001). ( D ) Representative photomicrographs and quantification of tube formation when HUVEC was seeded on Matrigel, followed by treatment with VEGF (10 ng/mL) with or without rhMG53 (50 μg/mL) for 18 h. rhMG53 significantly reduced tube length in VEGF-treated HUVEC ( n = 4; ** p = 0.0029). Magnification 4×. ( E ) HUVEC treated with IL-1B (10 ng/mL) with or without rhMG53 have decreased pSTAT3 protein expression; when normalized to total STAT3 expression, rhMG53 significantly (** p = 0.0084) decreased pSTAT3 ( n = 4). Statistical significance was assessed with the Kruskal–Wallis nonparametric test.

Article Snippet: Normal primary human vascular endothelial cells (HUVEC) were purchased from ATCC (Manassas, VA, USA) and grown in F-12K medium containing endothelial cell growth supplement.

Techniques: Migration, Control, Expressing